Advertisement

Summary of Prefrontal Molecular Abnormalities in the Stanley Foundation Neuropathology Consortium

  • Michael B. Knable
  • Beata M. Barci
  • Maree J. Webster
  • E. Fuller Torrey
Part of the Neurobiological Foundation of Aberrant Behaviors book series (NFAB, volume 4)

Abstract

Postmortem specimens from the Stanley Foundation Neuropathology Consortium, which contains matched samples from patients with schizophrenia, bipolar disorder, non-psychotic depression, and normal controls (n=15 per group), have been distributed to many research groups around the world. This chapter provides a summary of abnormal markers found in prefrontal cortical areas from this collection between 1997 and 2000. From 69 separate data sets, a total of 17 abnormal markers were identified that pertained to a variety of neural systems and processes including neuronal plasticity, neurotransmission, signal transduction, inhibitory interneuron function, and glial cells. Schizophrenia was associated with the largest number of abnormalities, many of which were also present in bipolar disorder. Major depression was associated with relatively few abnormalities. Most abnormal findings represented a decrease in protein or mRNA levels that could not be fully explained by exposure to psychotropic or illicit drugs or by other confounding variables. It is argued that the abnormal findings are not due to stochastic processes but represent viable markers for independent replication and further study as candidate genes or targets for new treatments.

Keywords

Bipolar Disorder Prefrontal Cortex Glial Fibrillary Acidic Protein Diagnostic Group Linear Discriminant Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995; 52: 258–266.PubMedCrossRefGoogle Scholar
  2. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP, Potkin SG, Sandman CA, Bunney WE Jr, Jones EG. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16: 19–30.PubMedGoogle Scholar
  3. Bayer TA, Schramm M, Feldmann N, Knable MB, Falkai P. Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 881–888.PubMedCrossRefGoogle Scholar
  4. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997; 24: 349–355.PubMedCrossRefGoogle Scholar
  5. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulated cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991; 48: 996–1001.PubMedCrossRefGoogle Scholar
  6. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. Increased GABA-A receptor binding in superficial layers of cingulated cortex in schizophrenics. J Neurosci 1992; 12: 924–929.PubMedGoogle Scholar
  7. Caberlotto L, Hurd YL. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport 1999; 10: 1747–1750.PubMedCrossRefGoogle Scholar
  8. Christie JM, Jane DE, Monaghan DT. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J Pharmacol Exp ther 2000; 292: 1169–1174.PubMedGoogle Scholar
  9. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed., Lawrence Erlbaum, Hillsdale, NJ, 1998; p 42.Google Scholar
  10. Coull MA, Lowther S, Katona CLE, Horton RW. Altered brain protein kinase C in depression: a postmortem study. Eur Neuropsychopharmacol 2000; 10: 283–288.PubMedCrossRefGoogle Scholar
  11. Daviss SR, Lewis DA. Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatry Res 1995; 59: 81–96.PubMedCrossRefGoogle Scholar
  12. Eastwood SL, Cairns NJ Harrison PJ. Synaptophysin gene expression in schizophrenia: investigation of synaptic pathology in the cerebral cortex. Br J Psychiatry 2000; 176: 236–242.PubMedCrossRefGoogle Scholar
  13. Fatemi SH. Reelin mutations in mouse and man: from reeler mouse to schizophrenia, mood disorders, autism and lissencephaly. Mol Psychiatry, in press.Google Scholar
  14. Frerking M, Nicoll RA. Synaptic kainate receptors. Curr Opin Neurobiol 2000; 10: 342–351.PubMedCrossRefGoogle Scholar
  15. Gabriel SM, Haroutunian V, Powchik P, Honer WG, Davidson M, Davies P, Davis KL. Increased concentrations of presynaptic proteins in the cingulated cortex of subjects with schizophrenia. Arch Gen Psychiatry 1997; 54: 559–566.PubMedCrossRefGoogle Scholar
  16. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, Barnes TR, Hirsch SR. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 1998; 65: 446–453.PubMedCrossRefGoogle Scholar
  17. Glantz LA, Lewis DA. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Arch Gen Psychiatry 1997; 54: 943–952.PubMedCrossRefGoogle Scholar
  18. Glantz LA, Austin MC, Lewis DA. Normal cellular levels of synaptophysin mRNA expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry 2000; 48: 389–397.PubMedCrossRefGoogle Scholar
  19. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 1997; 23: 437–458.PubMedCrossRefGoogle Scholar
  20. Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Vzonov D, Costa E. Decrease in reelin and glutamic acid decarboxylase 67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57: 1061–1069.PubMedCrossRefGoogle Scholar
  21. Guidotti A, Pesold C, Costa E. New neurochemical markers for psychosis: a working hypothesis of their operation. Neurochem Res 2000a; 25: 1207–1218.PubMedCrossRefGoogle Scholar
  22. Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ, Meador-Woodruff JH. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology 1998; 19: 278–286.PubMedGoogle Scholar
  23. Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 1999; 91: 1247–1255.PubMedCrossRefGoogle Scholar
  24. Hrdina P, Faludi G, Li Q, Bendotti C, Tekes K, Sotonyi P, Palkovits M. Growth-associated protein (GAP-43), its mRNA, and protein kinase C (PKC) isoenzymes in brain regions of depressed suicides. Mol Psychiatry 1998; 3: 411–418.PubMedCrossRefGoogle Scholar
  25. Impagnatiello F, Guidotti A, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, Uzunov DP, Smalheiser NR, Davis JM, Pandey GN, Pappas GD, Tueting P, Sharma RP, Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 15718–15723.PubMedCrossRefGoogle Scholar
  26. Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry 1994; 35: 84–95.PubMedCrossRefGoogle Scholar
  27. Jorgensen OS, Riederer P. Increased synaptic markers in hippocampus of depressed patients. J Neural Transm 1985; 64: 55–66.PubMedCrossRefGoogle Scholar
  28. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WST. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for `hypofrontality’. Mol Psychiatry 1999; 4: 39–45.PubMedCrossRefGoogle Scholar
  29. Kimble MB, Hyde TM, Murray AM, Herman MM, Kleinman JE. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls and normal controls. Biol Psychiatry 1996; 40: 1191–1199.CrossRefGoogle Scholar
  30. Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H. [3I]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77: 231–236.PubMedCrossRefGoogle Scholar
  31. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 2000; 157: 831–833.PubMedCrossRefGoogle Scholar
  32. Lahti RA, Cochrane EV, Roberts RC, Conley RR, Tamminga CA. [311]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons: an autoradiographic study. J Neural Transm 1998; 105: 507–516.PubMedCrossRefGoogle Scholar
  33. Lewis DA, Gonzalez-Burgos G. Intrinsic excitatory connections in the prefrontal cortex and the pathophysiology of schizophrenia. Brain Res Bull 2000; 52: 309–317.PubMedCrossRefGoogle Scholar
  34. Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986; 21: 1407–1414.PubMedCrossRefGoogle Scholar
  35. Mulcrone J, Kerwin RW. No difference in the expression of the D4 gene in postmortem frontal cortex from controls and schizophrenics. Neurosci Lett 1996; 219: 163–166.PubMedCrossRefGoogle Scholar
  36. Nowak G, Paul IA, Popik P, Young A, Skolnick P. Ca2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex. Eur J Pharmacol 1993; 247: 101–102.PubMedCrossRefGoogle Scholar
  37. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675: 157–164.PubMedCrossRefGoogle Scholar
  38. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 1998; 56: 207–217.PubMedCrossRefGoogle Scholar
  39. Ohnuma T, Augood SJ, Arai H, McKenna Pi, Emson PC. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 1999; 93: 441–448.PubMedCrossRefGoogle Scholar
  40. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007.PubMedCrossRefGoogle Scholar
  41. Ongur D, Drevets WC, Price JL. Glia1 reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290–13295.PubMedCrossRefGoogle Scholar
  42. Perrone-Bizzozero NI, Sower AC, Bird ED, Benowitz LI, Ivins KJ, Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Natl Acad Sci USA 1996; 93: 14182–14187.PubMedCrossRefGoogle Scholar
  43. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. Morphometric evidence for neuronal and glial prefrontal pathology in major depression. Biol Psychiatry 1999; 45: 1085–1098.PubMedCrossRefGoogle Scholar
  44. Roberts DA, Balderson D, Pickering-Brown SM, Deakin JFW, Owen F. The relative abundance of dopamine D4 receptor mRNA in postmortem brains of schizophrenics and controls. Schizophr Res 1996; 20: 171–174.PubMedCrossRefGoogle Scholar
  45. Schramm M, Falkai P, Feldmann N, Knable MB, Bayer TA. Reduced tyrosine kinase receptor C mRNA levels in the frontal cortex of patients with schizophrenia. Neurosci Lett 1998; 257: 65–68.PubMedCrossRefGoogle Scholar
  46. Shapiro J, Belmaker RH, Bigeon A, Seher A, Agam A. Scyllo-inositol in postmortem brain of suicide victims, bipolar, unipolar and schizophrenic patients. J Neural Transm, in press.Google Scholar
  47. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995; 52: 805–818.PubMedCrossRefGoogle Scholar
  48. Sokolov BP. Expression of NMDARI, GluR1, G1uR7, and KAI glutamate receptor mRNAs is decreased in frontal cortex of “neuroleptic-free” schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J Neurochem 1998; 71: 2454–2464.PubMedCrossRefGoogle Scholar
  49. Song L, Greendorfer AJ, Bartolucci AA, Jope RS. Phosphoinositide signal transduction system and G-protein levels in postmortem brain from subjects with bipolar disorder, major depression, and schizophrenia. J Psychiatr Res, in press.Google Scholar
  50. Thompson PM, Sower AC, Perrone-Bizzozero NI. Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia. Biol Psychiatry 1998; 43: 239–243.PubMedCrossRefGoogle Scholar
  51. Tom M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A. Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988; 78: 121–137.Google Scholar
  52. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation Brain Collection and Neuropathology Consortium. Schizophr Res 2000; 44: 151–155.PubMedCrossRefGoogle Scholar
  53. Uranova NA, Vostrikov VM, Olovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex area 9 in schizophrenia and mood disorders: A study of the Stanley Foundation Neuropathology Consortium. Submitted manuscript.Google Scholar
  54. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. Decreased glutamic acid decarboxylaseó7 messenger RNA expression in a subset of prefrontal cortical gammaaminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 2000; 57: 237–245.PubMedCrossRefGoogle Scholar
  55. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 2001; 158: 256–265.PubMedCrossRefGoogle Scholar
  56. Woo T, Miller JL, Lewis DA. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry 1997; 154: 1013–1015.PubMedGoogle Scholar
  57. Woo T-U, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gammaaminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 5341–5346.PubMedCrossRefGoogle Scholar
  58. Xing G, Post R. Reduced Nurrl (NOTI) and NGFI-B (TR3) expression in the prefrontal cortex of schizophrenic and unipolar patients. Submitted manuscript.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Michael B. Knable
  • Beata M. Barci
  • Maree J. Webster
  • E. Fuller Torrey

There are no affiliations available

Personalised recommendations